Royalty Pharma plc Class A Ordinary Shares
RPRXRoyalty Pharma plc (RPRX) is a pharmaceutical royalty financial company that acquires royalties from commercialized medicines, biotechnological innovations, and research and development programs. Established as a leading player in the royalty monetization sector, it provides capital to biopharmaceutical companies and researchers while generating revenue from the royalties it holds on successful drug sales.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 10, 2026 | $0.23 | 2026-05-15 | 2026-05-15 |
| March 10, 2026 | $0.23 | 2026-02-20 | 2026-02-20 |
| December 10, 2025 | $0.22 | 2025-11-14 | 2025-11-14 |
| September 10, 2025 | $0.22 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $0.22 | 2025-05-16 | 2025-05-16 |
Dividends Summary
- Consistent Payer: Royalty Pharma plc Class A Ordinary Shares has rewarded shareholders with 24 dividend payments over the past 6 years.
- Total Returned Value: Investors who held RPRX shares during this period received a total of $4.73 per share in dividend income.
- Latest Payout: The most recent dividend of $0.23/share was paid 38 days ago, on June 10, 2026.
- Yield & Schedule: RPRX currently pays dividends quarterly with an annual yield of 1.56%.
- Dividend Growth: Since 2020, the dividend payout has grown by 56.7%, from $0.15 to $0.23.
- Dividend Reliability: RPRX has maintained or increased its dividend for 24 consecutive payments.
Company News
Royalty Pharma announced the launch of the Royalty Pharma Translational Prize, a $1 million annual award recognizing exceptional achievements in translational medicine that bridge fundamental discovery and drug development. The prize will be administered independently and presented annually starting in spring 2027 at the Accelerating Bio-Innovati...
Royalty Pharma plc (NASDAQ: RPRX) announced a dividend of $0.235 per Class A ordinary share for Q2 2026, payable on June 10, 2026, to shareholders of record as of May 15, 2026. The company continues to generate returns from its portfolio of royalties on over 35 commercial pharmaceutical products.
Zymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executin...
Vera Therapeutics announced the appointment of Christopher Hite, Executive Vice President and Vice Chairman of Royalty Pharma, to its Board of Directors. Hite brings over 25 years of biopharmaceutical industry experience and will serve as an independent board member as the company prepares for the potential launch of atacicept, its first-in-class...
Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, based in Hong Kong. The move capitalizes on the rapidly growing Asian biotech market, where Chinese medicine out-licensing reached over $130 billion in transaction value in 2025, up from $14 billion in 2021. Sun, formerly Head of...
